Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trial.

ABSTRACT:

Aims

Concerns exist that intravenous (IV) iron might increase the risk of infections. The IRONMAN trial provided an opportunity to investigate whether giving IV ferric derisomaltose (FDI) to patients with heart failure and iron deficiency alters the rate of hospitalization or death due to infections.

Methods and results

IRONMAN was a randomized trial of IV FDI versus usual care in patients with symptomatic heart failure, left ventricular ejection fraction (LVEF) ≤45%, and transferrin saturation (TSAT) <20% or ferritin <100 μg/L. Infection was a pre-specified, blindly-adjudicated, safety endpoint. The primary analysis of interest was infection as the main reason for hospitalization or death, using first and recurrent events analyses. The composite primary event of interest te

SUBMITTER: Foley PW 

PROVIDER: S-EPMC11798631 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature